| CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity BD Choi, X Yu, AP Castano, AA Bouffard, A Schmidts, RC Larson, ... Nature biotechnology 37 (9), 1049-1058, 2019 | 499 | 2019 |
| CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma BD Choi, X Yu, AP Castano, H Darr, DB Henderson, AA Bouffard, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 287 | 2019 |
| CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours RC Larson, MC Kann, SR Bailey, NJ Haradhvala, PM Llopis, AA Bouffard, ... Nature 604 (7906), 563-570, 2022 | 269 | 2022 |
| Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma MJ Frigault, J Dietrich, M Martinez-Lage, M Leick, BD Choi, Z DeFilipp, ... Blood, The Journal of the American Society of Hematology 134 (11), 860-866, 2019 | 244 | 2019 |
| Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma Nature Medicine, 2022 | 158 | 2022 |
| Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome MR Hines, TE Knight, KO McNerney, MB Leick, T Jain, S Ahmed, ... Transplantation and cellular therapy 29 (7), 438. e1-438. e16, 2023 | 151 | 2023 |
| Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma BD Choi, ER Gerstner, MJ Frigault, MB Leick, CW Mount, L Balaj, ... New England Journal of Medicine 390 (14), 1290-1298, 2024 | 146 | 2024 |
| Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial MJ Frigault, J Dietrich, K Gallagher, M Roschewski, JT Jordan, D Forst, ... Blood, The Journal of the American Society of Hematology 139 (15), 2306-2315, 2022 | 105 | 2022 |
| Blockade or deletion of IFNγ reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies SR Bailey, S Vatsa, RC Larson, AA Bouffard, I Scarfò, MC Kann, ... Blood Cancer Discovery 3 (2), 136-153, 2022 | 97 | 2022 |
| Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia MB Leick, H Silva, I Scarfò, R Larson, BD Choi, AA Bouffard, K Gallagher, ... Cancer cell 40 (5), 494-508. e5, 2022 | 96 | 2022 |
| Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS) M Wehrli, K Gallagher, YB Chen, MB Leick, SL McAfee, AR El-Jawahri, ... Journal for immunotherapy of cancer 10 (1), e003847, 2022 | 95 | 2022 |
| Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy PG Miller, AS Sperling, EJ Brea, MB Leick, GG Fell, M Jan, SH Gohil, ... Blood advances 5 (15), 2982-2986, 2021 | 88 | 2021 |
| Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer MB Leick, CJ Shoff, EC Wang, JL Congress, GI Gallicano American journal of stem cells 1 (1), 59, 2011 | 63 | 2011 |
| The future of targeting FLT3 activation in AML MB Leick, MJ Levis Current hematologic malignancy reports 12 (3), 153-167, 2017 | 51 | 2017 |
| Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma A Schmidts, AA Srivastava, R Ramapriyan, SR Bailey, AA Bouffard, ... Neuro-Oncology Advances 5 (1), vdac185, 2023 | 38 | 2023 |
| SARS-CoV-2 T-cell immunity to variants of concern following vaccination KME Gallagher, MB Leick, RC Larson, TR Berger, K Katsis, JY Yam, ... BioRxiv, 2021 | 37 | 2021 |
| Clinical perspective: treatment of aggressive B cell lymphomas with FDA-approved CAR-T cell therapies MB Leick, MV Maus, MJ Frigault Molecular Therapy 29 (2), 433-441, 2021 | 32 | 2021 |
| Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicity CE Graham, WH Lee, HR Wiggin, VM Supper, MB Leick, F Birocchi, ... Blood 142 (14), 1248-1252, 2023 | 28 | 2023 |
| Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources A Schmidts, LC Marsh, AA Srivastava, AA Bouffard, AC Boroughs, I Scarfò, ... Journal for immunotherapy of cancer 8 (2), e000990, 2020 | 23 | 2020 |
| Mesothelin CAR T cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma M Wehrli, S Guinn, F Birocchi, A Kuo, Y Sun, RC Larson, AJ Almazan, ... Clinical Cancer Research 30 (9), 1859-1877, 2024 | 21 | 2024 |
Marcela V MausHarvard Medical SchoolEmail yang diverifikasi di mgh.harvard.edu